Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706537 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00706537 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 9 participants.
The verdict
NCT00706537, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treatment for non-alcoholic steatohepatitis (NASH). This study will investigate the steady-state safety, toleration and pharmacokinetics of multiple oral dose administration of CP-945598. Results will be used to estimate the pharmacokinetic characteristics in NASH patients and underwrite the safety of this compound prior to any further studies in NASH patients.
Interventions
- DRUG Placebo
- DRUG Active treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706537
The ClinicalTrials.gov registry entry for NCT00706537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00706537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706537 about?
NCT00706537 is a clinical study titled "Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH". CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treatment for non-alcoholic steatohepatitis (NASH). This study will investigate the steady-state safety, toleration an...
What is the current status of trial NCT00706537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-07. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00706537?
The interventions under investigation include: Placebo (DRUG), Active treatment (DRUG).
Who is sponsoring clinical trial NCT00706537?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.